The EPS miss and widening losses reflect heavy investment in Phase 3 trials and commercial infrastructure, typical for a pre-revenue biotech. The $960M cash runway funds multiple catalysts through 2027: VANQUISH data, SUNRISE enrollment, maintenance study Part 2 results, and VK3019 MAD initiation. Watch for ObesityWeek presentations in November and VANQUISH extension study commencement in 1Q27.
Price Chart
Executive Summary
Viking Therapeutics reported Q3 2026 net loss of $183.2M ($1.55/share), wider than the $90.8M loss in Q3 2025, driven by increased R&D and G&A spending as Phase 3 programs advance. The company initiated the SUNRISE oral Phase 3 program for VK2735, reported positive maintenance dosing data, and ended the quarter with $960M cash after a $575M upsized offering. No revenue was generated.
Key Financial Metrics
Key Facts
- Net loss of $183.2M for Q3 2026 vs $90.8M in Q3 2025
- EPS of -$1.55 vs consensus of -$1.06 (miss of 46.2%)
- Cash, cash equivalents and short-term investments of $960M at Sept 30, 2026, up from $706M at Dec 31, 2025
- Concurrent upsized public offerings of common stock and convertible senior notes raised gross proceeds of approximately $575M
- SUNRISE Phase 3 oral VK2735 program initiated (SUNRISE-1 and SUNRISE-2)
- Positive top-line results from Part 1 of VK2735 maintenance dosing study; Part 2 initiated
- Phase 1 SAD study of amylin agonist VK3019 nearing completion
- VANQUISH Phase 3 subcutaneous trials on track for completion in 2027
- Weighted-average shares outstanding increased to 118M from 112M year-over-year
Financial Impact
Net loss widened to $183.2M from $90.8M; EPS -$1.55 vs consensus -$1.06; cash position strengthened to $960M after $575M gross proceeds from offerings
Risk Factors
- EPS miss of 46% vs consensus may pressure near-term sentiment
- Dilution from 12.7M new shares and convertible notes (250.7M liability)
- No revenue; all value depends on clinical and regulatory success of VK2735
- Competitive obesity market with entrenched GLP-1/GIP players
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-436145 |
| Document: vktx-20261028.htm | 0001193125-26-436145 |
| Document: 0001193125-26-436145-index-headers.html | 0001193125-26-436145 |
| Document: 0001193125-26-436145-index.html | 0001193125-26-436145 |
| Document: 0001193125-26-436145.txt | 0001193125-26-436145 |
| 8-K Data (Synthetic) | 0001193125-26-436145 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 28, 2026 2d ago | 8-K | $26.86 $27.28 | ▲ +1.56% | ▲ +3.34% | $27.28 (+1.56%) |
Oct 23, 2026 7d ago | Institutional Cluster | $24.40 $24.21 | ▲ +0.78% | ▲ +1.49% | $27.28 (−11.80%) |
Oct 21, 2026 9d ago | Press Release | $25.83 $24.40 | ▼ −5.54% | ▼ −5.01% | $27.28 (+5.61%) |
Sep 28, 2026 4w ago | 8-K | $31.81 $32.60 | ▲ +2.48% | ▲ +2.69% | $27.28 (−14.24%) |
Sep 24, 2026 5w ago | 424B5 | $35.56 $33.03 | ▲ +7.11% | ▲ +6.37% | $27.28 (+23.28%) |
Sep 24, 2026 5w ago | 424B5 | $35.56 $33.03 | ▲ +7.11% | ▲ +6.37% | $27.28 (+23.28%) |
Sep 23, 2026 5w ago | 424B5 | $36.75 $35.56 | ▼ −3.24% | ▼ −3.78% | $27.28 (−25.77%) |
Sep 23, 2026 5w ago | 424B5 | $36.75 $35.56 | ▲ +3.24% | ▲ +3.78% | $27.28 (+25.77%) |
Sep 22, 2026 5w ago | 8-K | $40.85 $41.65 | ▲ +1.96% | ▲ +2.68% | $27.28 (−33.22%) |
Jul 29, 2026 13w ago | Insider Cluster | $33.11 $31.74 | ▼ −4.14% | ▼ −4.86% | $27.28 (−17.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers